Results 131 to 140 of about 2,524 (195)

Respiratory Pathogen Co-Detection in Hospitalized Infants with Bronchiolitis and Implementation of Universal Nirsevimab Immunoprophylaxis: A Six-Year Observational Study. [PDF]

Children (Basel)
Serra G, Martorana C, Barbera G, Catania M, Cipolla D, Colomba C, Farruggia P, Giuffrè M, La Malfa G, Greco M, Corsello G.   +10 more
europepmc   +1 more source

Comment on Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. <i>Vaccines</i> 2026, <i>14</i>, 411. [PDF]

Vaccines (Basel)
Hodges EN, Ghemmouri M, Neary MP, Gabriel V, Ottaviano C, Mari K, Ottobrino V, Chit A, Domachowske J, Yarnoff B, Musci R, Krilov LR.   +11 more
europepmc   +1 more source

Regional inequality in infant RSV morbidity and mortality burden in the era of expanded RSV passive immunisation: a global projection modelling study. [PDF]

EClinicalMedicine
Ren S, Cong B, Zou J, Guo L, Nair H, Sparrow E, Feikin DR, Li Y.   +7 more
europepmc   +1 more source

Estimating and Projecting Efficacy of Monoclonal Antibodies Against Respiratory Syncytial Virus Beyond Clinical Trial Periods. [PDF]

Vaccines (Basel)
Wang D, Lang JC, Kura K, Chen YH.
europepmc   +1 more source

Respiratory Syncytial Virus-Related Hospitalizations Among Infants Receiving Nirsevimab.

JAMA Netw Open
Buchan SA, Xie J, Bhatt M, Papenburg J, Goldfarb DM, Pernica JM, Burstein B, Gravel J, Berthelot S, Kam AJ, Poonai N, Eltorki M, Finkelstein Y, Sabhaney V, Cheng J, Gill PJ, Dickinson JA, Kwong JC, Freedman SB, SPRINT-KIDS Project Team.   +19 more
europepmc   +1 more source

Detection of nirsevimab-resistant RSV-B variants in children carrying the F:N201T substitution through genomic surveillance, Spain, 2025/26 season. [PDF]

Euro Surveill
Iglesias-Caballero M, Infantes JA, Campoy A, Camarero-Serrano S, Moreno S, Cano O, Vallejo-Palma G, González-Velasco C, Gaona C, Camacho-Martinez P, Merino-Diaz L, Vázquez-Morón S, Pozo F, Lepe JA, Mas V, Casas I.   +15 more
europepmc   +1 more source

Long-acting monoclonal antibodies and the evolving landscape of infant respiratory syncytial virus prevention. [PDF]

Pediatr Investig
Wang R, Abu-Raya B, Obeid H, Xie Z.
europepmc   +1 more source

Acute viral bronchiolitis before and after implementation of <i>nirsevimab</i> prophylaxis in Italy: a multicentre retrospective cohort study. [PDF]

Lancet Reg Health Eur
Spatuzzo M, Corsello A, Riccò M, Bonci E, Di Francesco D, Strati MF, Amodio G, Manzalini R, Costantini E, Mazzotti S, Renni M, Coralluzzo F, Langone L, Fiumicelli E, Albonico G, Adornato S, Passarella V, Piras A, Forcucci F, Capuano MC, Basile A, Albini M, Cafforio A, Coppola C, Palmoni M, Bertolucci G, Bertolo S, Di Febo C, Donato A, Di Pasquale G, Toscano F, Tolfa G, Arpinelli M, Marseglia GL, Agostiniani R, Midulla F, ONSP-RSV Study Group.   +36 more
europepmc   +1 more source

Cost-Effectiveness of Maternal RSVpreF Vaccination Compared with Newborn Nirsevimab RSV Prophylaxis or No RSV Prophylaxis in Switzerland. [PDF]

Appl Health Econ Health Policy
Bainbridge J, Mealing S, Graham C, Jenal M, von Dombrowski N, Dymond A.   +5 more
europepmc   +1 more source

Pediatricians' attitudes and knowledge of RSV immunization products: A multi-country cross-sectional survey. [PDF]

PLoS One
Di Chiara C, Piché-Renaud PP, Rigamonti V, Cantarutti A, Calvo C, Rivero Calle I, Soriano-Arandes A, Giaquinto C, Cantarutti L, Donà D, Lo Vecchio A, Hadjipanayis A, Pana ZD, Kopsidas I, Rose A, Tagarro A, Morris SK.   +16 more
europepmc   +1 more source